Heart failure & cardiomyopathies
Therapeutic Effects of Heart Failure Medical Therapies on Standardized Kidney Outcomes: Comprehensive Individual Participant–Level Analysis of 6 Randomized Clinical Trials
Authors' conclusion
When applying standardized stringent kidney end point definitions, steroidal mineralocorticoid receptor antagonists, angiotensin receptor-neprilysin inhibitor, and SGLT2 inhibitors have either neutral or beneficial effects on kidney outcomes in heart failure.
Study context
- Population
- Patients with HF in 6 contemporary trials
- Participants
- 28,690 patients · 6 RCTs
- Comparison
- Steroidal MRA, ARNI and SGLT2 inhibitors vs control
- Outcome
- Standardized composite kidney end point: sustained eGFR decline by 40%, 50% or 57% (confirmed ≥30 days later), end-stage kidney disease or renal death
Methodological detailsstandardized kidney end point definitions
- Standardized kidney end point definitions
Pooled result
As reported in the abstract
Composite kidney end point by eGFR threshold
Proportion with end point, estimated glomerular filtration rate (eGFR) threshold 57%
0.3% to 3.3%
Proportion with end point, eGFR threshold 40%
1.0% to 10.0%
Original publication
Therapeutic Effects of Heart Failure Medical Therapies on Standardized Kidney Outcomes: Comprehensive Individual Participant–Level Analysis of 6 Randomized Clinical Trials. Circulation. Published 1 September 2024. doi:10.
Summarised from the published abstract; every number is checked against it